Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Clinical characteristics of human herpesvirus 7 (HHV-7) reactivation following umbilical cord blood transplantation: A retrospective study

Kai Ishimaru, Shinsuke Takagi, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2025-4195

Published: 2025

Journal Articles

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft-versus-host disease following umbilical cord blood transplantation

Mika Kuno, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2025-7757

Published: 2025

Journal Articles

Clinical characteristics and whole-exome sequencing-based genomic profiling of post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Tatsuro Hirao, Daisuke Kaji, Yuki Shimizu, Kenichi Makishima, Mamiko Sakata-Yanagimoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2025-1760

Published: 2025

Journal Articles

Novel prognostic scoring system for hematopoietic stem cell transplantation in myelodysplastic syndrome and Acute Myeloid Leukemia, myelodysplasia-related

Shunsuke Nishino, Hisashi Yamamoto, Go Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Yuki Asano-Mori, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 7829.

https://doi.org/10.1182/blood-2025-7829

Published: 2025

Journal Articles

A single-institution retrospective analysis of allo-HSCT for relapsed and refractory aggressive lymphomas: T-cell origin predicts better outcomes even in active disease.

Futoshi Yoshino, Daisuke Kaji, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2025) 146 (Supplement 1): 7822.

https://doi.org/10.1182/blood-2025-7822

Published: 2025

Journal Articles

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

Rikako Tabata, Daisuke Kaji, Go Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2025-1942

Published: 2025

Journal Articles

Single-unit cord blood transplantation reduces the risk of relapse and improves leukemia-free survival compared to other donor sources in allo-HSCT for patients with high-risk acute myeloid leukemia

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 591.

https://doi.org/10.1182/blood-2025-591

Published: 2025

Journal Articles

Tailoring TBI for vulnerable patients: 8 gy TBI shows comparable outcomes to 12 gy TBI in adult ALL allo-HSCT

Tomoyo Kubo, Shinsuke Takagi, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Aya Nishida, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Atsushi Wake, Yuki Asano-Mori, Go Yamamoto, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 5971.

https://doi.org/10.1182/blood-2025-5971

Published: 2025

Journal Articles

CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival

Shogo Matsui, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 7787.

https://doi.org/10.1182/blood-2025-7787

Published: 2025

Journal Articles

Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis

Blood (2025) 146 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2025-2492

Published: 2025

Journal Articles

Temporal trends in treatment outcomes of acute lymphoblastic leukemia in Japan: Progress and unmet needs

Ryo Koizumi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2025) 146 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2025-1553

Published: 2025

Journal Articles

Low serum IgG at apheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR T-cell therapy for B-cell lymphoma

Daisuke Kaji, Tatsuro Hirao, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2025) 146 (Supplement 1): 5492.

https://doi.org/10.1182/blood-2025-5492

Published: 2025

Journal Articles

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2024-198879

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2024-210383

Published: 2024

Journal Articles

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Yuki Taya, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2024-208778

Published: 2024

Journal Articles

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Shunsuke Nishino, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2024-205008

Published: 2024

Journal Articles

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Jotaro Yamamoto, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2024-201930

Published: 2024

Journal Articles

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Ryo Koizumi, Shinsuke Takagi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2024-203327

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2023-188946

Published: 2023

Journal Articles

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Kazuya Ishiwata, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6931.

https://doi.org/10.1182/blood-2023-184637

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Clinical characteristics of human herpesvirus 7 (HHV-7) reactivation following umbilical cord blood transplantation: A retrospective study

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft-versus-host disease following umbilical cord blood transplantation

Clinical characteristics and whole-exome sequencing-based genomic profiling of post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Novel prognostic scoring system for hematopoietic stem cell transplantation in myelodysplastic syndrome and Acute Myeloid Leukemia, myelodysplasia-related

A single-institution retrospective analysis of allo-HSCT for relapsed and refractory aggressive lymphomas: T-cell origin predicts better outcomes even in active disease.

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

Single-unit cord blood transplantation reduces the risk of relapse and improves leukemia-free survival compared to other donor sources in allo-HSCT for patients with high-risk acute myeloid leukemia

Tailoring TBI for vulnerable patients: 8 gy TBI shows comparable outcomes to 12 gy TBI in adult ALL allo-HSCT

CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival

Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis

Temporal trends in treatment outcomes of acute lymphoblastic leukemia in Japan: Progress and unmet needs

Low serum IgG at apheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR T-cell therapy for B-cell lymphoma

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only